Annexon to Present at the Raymond James Human Health Innovation Conference - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
















		
		

 



	

		

			

				
			

		

		                
                

                    

                        

        									

                        								

							

							
clinical pipeline

							
for diseases of the  body, brain & eye

						

        									

                        

											
												

													
													

														
Ben Barres, MD, PhD

														
CO-FOUNDER, ANNEXON, FORMER CHAIR OF NEUROBIOLOGY, STANFORD UNIVERSITY

														
Dr. Barres co-founded Annexon Biosciences and was a Professor and Chair of Neurobiology at Stanford University School of Medicine. He received his BS from Massachusetts Institute of Technology, his MD from Dartmouth Medical School and his PhD at Harvard Medical School in the laboratory of David Corey. Dr. Barres completed his internship and residency in neurology at the Cornell Cooperating Hospitals Program and his postdoctoral fellowship with Martin Raff at University College London. Dr. Barres won many teaching awards at Stanford and was the creator and director of the Masters of Science in Medicine Program, a program at Stanford University designed to train PhD students in human biology and disease. He was a founding member of the Myelin Repair Foundation that focuses on translational research to develop new drugs for multiple sclerosis. Dr. Barres was a Fellow of the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. His laboratory research focused on the role of neuron-glial interactions in the central nervous system.

													

												

											
                    

                

            
    
   

            
            
Annexon to Present at the Raymond James Human Health Innovation Conference


            June 16, 2021


            
SOUTH SAN FRANCISCO, Calif., June  16, 2021  (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the virtual Raymond James Human Health Innovation Conference on June 23rd, 2021 at 1:20 pm EDT.


A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.


About Annexon, Inc.
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.


Investor Contacts:

Jennifer Lew, Chief Financial Officer, Annexon Biosciences, jlew@annexonbio.com

Sara Michelmore smichelmore@macbiocom.com


Media Contact:

Miriam Mason, Annexon Biosciences, mmason@annexonbio.com


            

« back to news page    

    





	

		

			

				

					

						
Contact Us

						

							info@annexonbio.com

							650.822.5500
						

					

					

						
Annexon, Inc.

						
1400 Sierra Point Parkway, Building C, 
2nd Floor

						Brisbane, CA 94005

					

					

							
							
					

				

				

                    
					
© 2024 Annexon, Inc.  All rights reserved.